Wall Street analysts forecast that PerkinElmer, Inc. (NYSE:PKI) will announce $552.30 million in sales for the current quarter, Zacks reports. Six analysts have provided estimates for PerkinElmer’s earnings, with the lowest sales estimate coming in at $550.00 million and the highest estimate coming in at $553.20 million. PerkinElmer posted sales of $548.05 million in the same quarter last year, which suggests a positive year over year growth rate of 0.8%. The company is scheduled to report its next quarterly earnings results on Monday, November 6th.

On average, analysts expect that PerkinElmer will report full-year sales of $552.30 million for the current financial year, with estimates ranging from $2.21 billion to $2.24 billion. For the next fiscal year, analysts forecast that the firm will post sales of $2.32 billion per share, with estimates ranging from $2.30 billion to $2.34 billion. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow PerkinElmer.

PerkinElmer (NYSE:PKI) last announced its quarterly earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.67. PerkinElmer had a return on equity of 13.44% and a net margin of 16.80%. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $554.14 million. During the same quarter in the previous year, the business earned $0.67 EPS. PerkinElmer’s revenue was up 2.0% compared to the same quarter last year.

Several equities analysts have recently commented on the stock. Cantor Fitzgerald restated a “hold” rating on shares of PerkinElmer in a report on Sunday, July 16th. Zacks Investment Research upgraded shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $78.00 price objective on the stock in a report on Wednesday, July 19th. Piper Jaffray Companies upped their price objective on shares of PerkinElmer to $80.00 and gave the stock an “overweight” rating in a report on Tuesday, July 25th. Wells Fargo & Company assumed coverage on shares of PerkinElmer in a report on Thursday, July 13th. They issued a “market perform” rating and a $72.00 price objective on the stock. Finally, Morgan Stanley restated an “overweight” rating and issued a $79.00 price objective (up from $73.00) on shares of PerkinElmer in a report on Monday, July 10th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the stock. PerkinElmer presently has a consensus rating of “Hold” and a consensus target price of $67.00.

COPYRIGHT VIOLATION NOTICE: “Brokerages Anticipate PerkinElmer, Inc. (PKI) Will Post Quarterly Sales of $552.30 Million” was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/09/18/brokerages-anticipate-perkinelmer-inc-pki-will-post-quarterly-sales-of-552-30-million.html.

PerkinElmer (PKI) opened at 69.07 on Monday. PerkinElmer has a one year low of $45.35 and a one year high of $70.16. The stock has a market cap of $7.61 billion, a P/E ratio of 20.83 and a beta of 0.74. The company’s 50-day moving average price is $65.89 and its 200-day moving average price is $62.89.

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 10th. Shareholders of record on Friday, October 20th will be issued a dividend of $0.07 per share. The ex-dividend date of this dividend is Thursday, October 19th. This represents a $0.28 dividend on an annualized basis and a yield of 0.41%. PerkinElmer’s dividend payout ratio (DPR) is presently 8.46%.

A number of institutional investors have recently added to or reduced their stakes in PKI. Waldron LP acquired a new stake in PerkinElmer during the 1st quarter worth approximately $233,000. Russell Investments Group Ltd. lifted its holdings in PerkinElmer by 13.4% during the 1st quarter. Russell Investments Group Ltd. now owns 21,459 shares of the medical research company’s stock worth $1,245,000 after buying an additional 2,531 shares in the last quarter. Canada Pension Plan Investment Board lifted its holdings in PerkinElmer by 143.5% during the 1st quarter. Canada Pension Plan Investment Board now owns 5,600 shares of the medical research company’s stock worth $325,000 after buying an additional 3,300 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in PerkinElmer by 2.7% during the 1st quarter. Bank of New York Mellon Corp now owns 1,049,537 shares of the medical research company’s stock worth $60,937,000 after buying an additional 27,484 shares in the last quarter. Finally, LS Investment Advisors LLC lifted its holdings in PerkinElmer by 36.9% during the 1st quarter. LS Investment Advisors LLC now owns 2,817 shares of the medical research company’s stock worth $164,000 after buying an additional 759 shares in the last quarter. Institutional investors own 91.47% of the company’s stock.

PerkinElmer Company Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Get a free copy of the Zacks research report on PerkinElmer (PKI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.